{"id":31180,"date":"2025-04-03T16:00:22","date_gmt":"2025-04-03T08:00:22","guid":{"rendered":"https:\/\/flcube.com\/?p=31180"},"modified":"2025-04-03T16:00:23","modified_gmt":"2025-04-03T08:00:23","slug":"nurix-therapeutics-expands-sanofi-partnership-with-undisclosed-tpd-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31180","title":{"rendered":"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program"},"content":{"rendered":"\n

US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX<\/a>) announced an expanded partnership with Sanofi (EPA: SAN<\/a>, NASDAQ: SNY<\/a>). The French pharmaceutical giant has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.<\/p>\n\n\n\n

Partnership Details<\/strong>
Under the terms of the agreement, Nurix will receive an upfront payment of USD 15 million and is eligible for development, regulatory, and commercial milestone payments totaling up to USD 465 million, along with sales-based royalties.<\/p>\n\n\n\n

Historical Collaboration<\/strong>
This expanded collaboration builds on the initial partnership established in 2019, through which Sanofi secured rights to a STAT6 degrader program from Nurix. The ongoing relationship underscores the potential of Nurix’s protein degradation technology in addressing complex therapeutic challenges.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership…<\/p>\n","protected":false},"author":1,"featured_media":31181,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[931,1156,867,1084,147],"class_list":["post-31180","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-epa-san","tag-nasdaq-nrix","tag-nasdaq-sny","tag-nurix-therapeutics","tag-sanofi"],"yoast_head":"\nNurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership with Sanofi (EPA: SAN, NASDAQ: SNY). The French pharmaceutical giant has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31180\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program\" \/>\n<meta property=\"og:description\" content=\"US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership with Sanofi (EPA: SAN, NASDAQ: SNY). The French pharmaceutical giant has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31180\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-03T08:00:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-03T08:00:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0303-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program\",\"datePublished\":\"2025-04-03T08:00:22+00:00\",\"dateModified\":\"2025-04-03T08:00:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180\"},\"wordCount\":131,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0303-png.webp\",\"keywords\":[\"EPA: SAN\",\"NASDAQ: NRIX\",\"NASDAQ: SNY\",\"Nurix Therapeutics\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31180#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31180\",\"name\":\"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0303-png.webp\",\"datePublished\":\"2025-04-03T08:00:22+00:00\",\"dateModified\":\"2025-04-03T08:00:23+00:00\",\"description\":\"US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership with Sanofi (EPA: SAN, NASDAQ: SNY). The French pharmaceutical giant has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31180\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0303-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0303-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31180#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program - Insight, China's Pharmaceutical Industry","description":"US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership with Sanofi (EPA: SAN, NASDAQ: SNY). The French pharmaceutical giant has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31180","og_locale":"en_US","og_type":"article","og_title":"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program","og_description":"US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership with Sanofi (EPA: SAN, NASDAQ: SNY). The French pharmaceutical giant has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=31180","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-03T08:00:22+00:00","article_modified_time":"2025-04-03T08:00:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0303-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31180#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31180"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program","datePublished":"2025-04-03T08:00:22+00:00","dateModified":"2025-04-03T08:00:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31180"},"wordCount":131,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31180#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0303-png.webp","keywords":["EPA: SAN","NASDAQ: NRIX","NASDAQ: SNY","Nurix Therapeutics","Sanofi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31180#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31180","url":"https:\/\/flcube.com\/?p=31180","name":"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31180#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31180#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0303-png.webp","datePublished":"2025-04-03T08:00:22+00:00","dateModified":"2025-04-03T08:00:23+00:00","description":"US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership with Sanofi (EPA: SAN, NASDAQ: SNY). The French pharmaceutical giant has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31180#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31180"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31180#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0303-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0303-png.webp","width":1080,"height":608,"caption":"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31180#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0303-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31180"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31180\/revisions"}],"predecessor-version":[{"id":31182,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31180\/revisions\/31182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31181"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}